{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:21:30Z","timestamp":1793647290260,"version":"4.5.1"},"reference-count":247,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL130020"],"award-info":[{"award-number":["R01 HL130020"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL146690"],"award-info":[{"award-number":["R01 HL146690"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI195484"],"award-info":[{"award-number":["U01 AI195484"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 TR006031"],"award-info":[{"award-number":["UM1 TR006031"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-02214578"],"award-info":[{"award-number":["RS-2025-02214578"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00353746"],"award-info":[{"award-number":["RS-2024-00353746"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF21CC0073729"],"award-info":[{"award-number":["NNF21CC0073729"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41591-026-04584-3","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:04:07Z","timestamp":1787821447000},"page":"3164-3180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Induced pluripotent stem cells from discovery to translation"],"prefix":"10.1038","volume":"32","author":[{"given":"Jaecheol","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3995-2306","authenticated-orcid":false,"given":"Todd","family":"Herron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0741-7987","authenticated-orcid":false,"given":"Lorenz","family":"Studer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-6535","authenticated-orcid":false,"given":"Christine L.","family":"Mummery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-8041","authenticated-orcid":false,"given":"Joseph C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"4584_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663\u2013676 (2006).","journal-title":"Cell"},{"key":"4584_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u2013872 (2007).","journal-title":"Cell"},{"key":"4584_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247125","volume":"345","author":"MA Lancaster","year":"2014","unstructured":"Lancaster, M. A. & Knoblich, J. A. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 345, 1247125 (2014).","journal-title":"Science"},{"key":"4584_CR4","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers, H. Modeling development and disease with organoids. Cell 165, 1586\u20131597 (2016).","journal-title":"Cell"},{"key":"4584_CR5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cell.2011.06.019","volume":"146","author":"F Soldner","year":"2011","unstructured":"Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318\u2013331 (2011).","journal-title":"Cell"},{"key":"4584_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38704-1","volume":"14","author":"DR Neavin","year":"2023","unstructured":"Neavin, D. R. et al. A village in a dish model system for population-scale hiPSC studies. Nat. Commun. 14, 3240 (2023).","journal-title":"Nat. Commun."},{"key":"4584_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.stem.2023.01.010","volume":"30","author":"MF Wells","year":"2023","unstructured":"Wells, M. F. et al. Natural variation in gene expression and viral susceptibility revealed by neural progenitor cell villages. Cell Stem Cell 30, 312\u2013332 (2023).","journal-title":"Cell Stem Cell"},{"key":"4584_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nbt.4042","volume":"36","author":"HM Kang","year":"2018","unstructured":"Kang, H. M. et al. Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. Nat. Biotechnol. 36, 89\u201394 (2018).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","volume":"167","author":"PT Sager","year":"2014","unstructured":"Sager, P. T., Gintant, G., Turner, J. R., Pettit, S. & Stockbridge, N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 167, 292\u2013300 (2014).","journal-title":"Am. Heart J."},{"key":"4584_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jphs.2018.02.005","volume":"136","author":"D Yamazaki","year":"2018","unstructured":"Yamazaki, D. et al. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes. J. Pharmacol. Sci. 136, 249\u2013256 (2018).","journal-title":"J. Pharmacol. Sci."},{"key":"4584_CR11","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","volume":"24","author":"K Blinova","year":"2018","unstructured":"Blinova, K. et al. International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Rep. 24, 3582\u20133592 (2018).","journal-title":"Cell Rep."},{"key":"4584_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/2168479018795117","volume":"53","author":"DG Strauss","year":"2019","unstructured":"Strauss, D. G. et al. Comprehensive in vitro Proarrhythmia Assay (CiPA) update from a Cardiac Safety Research Consortium \/ Health and Environmental Sciences Institute \/ FDA meeting. Ther. Innov. Regul. Sci. 53, 519\u2013525 (2019).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"4584_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-pharmtox-010919-023309","volume":"60","author":"T de Korte","year":"2020","unstructured":"de Korte, T. et al. Unlocking personalized biomedicine and drug discovery with human induced pluripotent stem cell-derived cardiomyocytes: fit for purpose or forever elusive? Annu. Rev. Pharmacol. Toxicol. 60, 529\u2013551 (2020).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"4584_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104756","volume":"117","author":"G Gintant","year":"2020","unstructured":"Gintant, G. et al. Repolarization studies using human stem cell-derived cardiomyocytes: validation studies and best practice recommendations. Regul. Toxicol. Pharmacol. 117, 104756 (2020).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"4584_CR15","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","volume":"376","author":"M Mandai","year":"2017","unstructured":"Mandai, M. et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376, 1038\u20131046 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4584_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nature23664","volume":"548","author":"T Kikuchi","year":"2017","unstructured":"Kikuchi, T. et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson\u2019s disease model. Nature 548, 592\u2013596 (2017).","journal-title":"Nature"},{"key":"4584_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","volume":"641","author":"N Sawamoto","year":"2025","unstructured":"Sawamoto, N. et al. Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease. Nature 641, 971\u2013977 (2025).","journal-title":"Nature"},{"key":"4584_CR18","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1126\/science.aeg9252","volume":"391","author":"D Normile","year":"2026","unstructured":"Normile, D. Stem cell therapies \u2018come of age\u2019 with two conditional approvals in Japan. Science 391, 964\u2013965 (2026).","journal-title":"Science"},{"key":"4584_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","volume":"27","author":"S Yamanaka","year":"2020","unstructured":"Yamanaka, S. Pluripotent stem cell-based cell therapy\u2014promise and challenges. Cell Stem Cell 27, 523\u2013531 (2020).","journal-title":"Cell Stem Cell"},{"key":"4584_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.stemcr.2015.12.009","volume":"6","author":"A Kyttala","year":"2016","unstructured":"Kyttala, A. et al. Genetic variability overrides the impact of parental cell type and determines iPSC differentiation potential. Stem Cell Reports 6, 200\u2013212 (2016).","journal-title":"Stem Cell Reports"},{"key":"4584_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.stemcr.2016.05.001","volume":"6","author":"GQ Daley","year":"2016","unstructured":"Daley, G. Q. et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines. Stem Cell Reports 6, 787\u2013797 (2016).","journal-title":"Stem Cell Reports"},{"key":"4584_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature22312","volume":"545","author":"FT Merkle","year":"2017","unstructured":"Merkle, F. T. et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 545, 229\u2013233 (2017).","journal-title":"Nature"},{"key":"4584_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nbt1374","volume":"26","author":"M Nakagawa","year":"2008","unstructured":"Nakagawa, M. et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26, 101\u2013106 (2008).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ncb3193","volume":"17","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. The oncogene c-Jun impedes somatic cell reprogramming. Nat. Cell Biol. 17, 856\u2013867 (2015).","journal-title":"Nat. Cell Biol."},{"key":"4584_CR25","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41556-018-0136-x","volume":"20","author":"T Mai","year":"2018","unstructured":"Mai, T. et al. NKX3-1 is required for induced pluripotent stem cell reprogramming and can replace OCT4 in mouse and human iPSC induction. Nat. Cell Biol. 20, 900\u2013908 (2018).","journal-title":"Nat. Cell Biol."},{"key":"4584_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.stem.2019.10.002","volume":"25","author":"S Velychko","year":"2019","unstructured":"Velychko, S. et al. Excluding Oct4 from Yamanaka cocktail unleashes the developmental potential of iPSCs. Cell Stem Cell 25, 737\u2013753 (2019).","journal-title":"Cell Stem Cell"},{"key":"4584_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1126\/science.1239278","volume":"341","author":"P Hou","year":"2013","unstructured":"Hou, P. et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341, 651\u2013654 (2013).","journal-title":"Science"},{"key":"4584_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nature07863","volume":"458","author":"K Woltjen","year":"2009","unstructured":"Woltjen, K. et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766\u2013770 (2009).","journal-title":"Nature"},{"key":"4584_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2009.02.013","volume":"136","author":"F Soldner","year":"2009","unstructured":"Soldner, F. et al. Parkinson\u2019s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964\u2013977 (2009).","journal-title":"Cell"},{"key":"4584_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1634\/stemcells.2008-1075","volume":"27","author":"CA Sommer","year":"2009","unstructured":"Sommer, C. A. et al. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27, 543\u2013549 (2009).","journal-title":"Stem Cells"},{"key":"4584_CR31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.1162494","volume":"322","author":"M Stadtfeld","year":"2008","unstructured":"Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G. & Hochedlinger, K. Induced pluripotent stem cells generated without viral integration. Science 322, 945\u2013949 (2008).","journal-title":"Science"},{"key":"4584_CR32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.stem.2009.05.005","volume":"4","author":"D Kim","year":"2009","unstructured":"Kim, D. et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4, 472\u2013476 (2009).","journal-title":"Cell Stem Cell"},{"key":"4584_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.stem.2009.04.005","volume":"4","author":"H Zhou","year":"2009","unstructured":"Zhou, H. et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4, 381\u2013384 (2009).","journal-title":"Cell Stem Cell"},{"key":"4584_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2183\/pjab.85.348","volume":"85","author":"N Fusaki","year":"2009","unstructured":"Fusaki, N., Ban, H., Nishiyama, A., Saeki, K. & Hasegawa, M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 85, 348\u2013362 (2009).","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"4584_CR35","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.stem.2010.08.012","volume":"7","author":"L Warren","year":"2010","unstructured":"Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618\u2013630 (2010).","journal-title":"Cell Stem Cell"},{"key":"4584_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nmeth.1426","volume":"7","author":"F Jia","year":"2010","unstructured":"Jia, F. et al. A nonviral minicircle vector for deriving human iPS cells. Nat. Methods 7, 197\u2013199 (2010).","journal-title":"Nat. Methods"},{"key":"4584_CR37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41551-017-0141-6","volume":"1","author":"JM Churko","year":"2017","unstructured":"Churko, J. M. et al. Transcriptomic and epigenomic differences in human induced pluripotent stem cells generated from six reprogramming methods. Nat. Biomed. Eng. 1, 826\u2013837 (2017).","journal-title":"Nat. Biomed. Eng."},{"key":"4584_CR38","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.stem.2009.08.021","volume":"5","author":"A Haase","year":"2009","unstructured":"Haase, A. et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 5, 434\u2013441 (2009).","journal-title":"Cell Stem Cell"},{"key":"4584_CR39","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1681\/ASN.2011010106","volume":"22","author":"T Zhou","year":"2011","unstructured":"Zhou, T. et al. Generation of induced pluripotent stem cells from urine. J. Am. Soc. Nephrol. 22, 1221\u20131228 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4584_CR40","doi-asserted-by":"publisher","first-page":"15720","DOI":"10.1073\/pnas.0908450106","volume":"106","author":"N Sun","year":"2009","unstructured":"Sun, N. et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc. Natl Acad. Sci. USA 106, 15720\u201315725 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4584_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature07677","volume":"457","author":"AD Ebert","year":"2009","unstructured":"Ebert, A. D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277\u2013280 (2009).","journal-title":"Nature"},{"key":"4584_CR42","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1126\/science.1158799","volume":"321","author":"JT Dimos","year":"2008","unstructured":"Dimos, J. T. et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218\u20131221 (2008).","journal-title":"Science"},{"key":"4584_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature08320","volume":"461","author":"G Lee","year":"2009","unstructured":"Lee, G. et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461, 402\u2013406 (2009).","journal-title":"Nature"},{"key":"4584_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature12517","volume":"501","author":"MA Lancaster","year":"2013","unstructured":"Lancaster, M. A. et al. Cerebral organoids model human brain development and microcephaly. Nature 501, 373\u2013379 (2013).","journal-title":"Nature"},{"key":"4584_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nature22330","volume":"545","author":"F Birey","year":"2017","unstructured":"Birey, F. et al. Assembly of functionally integrated human forebrain spheroids. Nature 545, 54\u201359 (2017).","journal-title":"Nature"},{"key":"4584_CR46","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nm.3545","volume":"20","author":"G Wang","year":"2014","unstructured":"Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616\u2013623 (2014).","journal-title":"Nat. Med."},{"key":"4584_CR47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-018-0858-8","volume":"565","author":"RA Wimmer","year":"2019","unstructured":"Wimmer, R. A. et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature 565, 505\u2013510 (2019).","journal-title":"Nature"},{"key":"4584_CR48","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41592-022-01591-3","volume":"19","author":"S Cho","year":"2022","unstructured":"Cho, S., Discher, D. E., Leong, K. W., Vunjak-Novakovic, G. & Wu, J. C. Challenges and opportunities for the next generation of cardiovascular tissue engineering. Nat. Methods 19, 1064\u20131071 (2022).","journal-title":"Nat. Methods"},{"key":"4584_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/science.adu9375","volume":"388","author":"OJ Abilez","year":"2025","unstructured":"Abilez, O. J. et al. Gastruloids enable modeling of the earliest stages of human cardiac and hepatic vascularization. Science 388, eadu9375 (2025).","journal-title":"Science"},{"key":"4584_CR50","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nbt.1927","volume":"29","author":"D Hockemeyer","year":"2011","unstructured":"Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731\u2013734 (2011).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR51","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"4584_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"4584_CR53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse, T. et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat. Biotechnol. 37, 252\u2013258 (2019).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR54","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nm.4087","volume":"22","author":"PW Burridge","year":"2016","unstructured":"Burridge, P. W. et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547\u2013556 (2016).","journal-title":"Nat. Med."},{"key":"4584_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14457-z","volume":"11","author":"ASE Cuomo","year":"2020","unstructured":"Cuomo, A. S. E. et al. Single-cell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene expression. Nat. Commun. 11, 810 (2020).","journal-title":"Nat. Commun."},{"key":"4584_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100573","volume":"3","author":"G Lozachmeur","year":"2023","unstructured":"Lozachmeur, G. et al. Three-dimensional molecular cartography of human cerebral organoids revealed by double-barcoded spatial transcriptomics. Cell Rep. Methods 3, 100573 (2023).","journal-title":"Cell Rep. Methods"},{"key":"4584_CR57","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.cell.2026.02.012","volume":"189","author":"W Liu","year":"2026","unstructured":"Liu, W., Pang, P. D., Wu, C. A., Tagle, D. & Wu, J. C. New approach methodologies for drug discovery. Cell 189, 1877\u20131903 (2026).","journal-title":"Cell"},{"key":"4584_CR58","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1126\/science.aeb0045","volume":"392","author":"X Wu","year":"2026","unstructured":"Wu, X., Wu, M. A., Zou, J., Kleinstreuer, N. & Wu, J. C. Reimagining human-centric drug development with new approach methodologies. Science 392, 371\u2013378 (2026).","journal-title":"Science"},{"key":"4584_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nature09747","volume":"471","author":"I Itzhaki","year":"2011","unstructured":"Itzhaki, I. et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225\u2013229 (2011).","journal-title":"Nature"},{"key":"4584_CR60","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa0908679","volume":"363","author":"A Moretti","year":"2010","unstructured":"Moretti, A. et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363, 1397\u20131409 (2010).","journal-title":"N. Engl. J. Med."},{"key":"4584_CR61","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nbt.1562","volume":"27","author":"D Hockemeyer","year":"2009","unstructured":"Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27, 851\u2013857 (2009).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.stem.2009.05.023","volume":"5","author":"J Zou","year":"2009","unstructured":"Zou, J. et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5, 97\u2013110 (2009).","journal-title":"Cell Stem Cell"},{"key":"4584_CR63","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1534\/genetics.110.120717","volume":"186","author":"M Christian","year":"2010","unstructured":"Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757\u2013761 (2010).","journal-title":"Genetics"},{"key":"4584_CR64","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nprot.2011.431","volume":"7","author":"NE Sanjana","year":"2012","unstructured":"Sanjana, N. E. et al. A transcription activator-like effector toolbox for genome engineering. Nat. Protoc. 7, 171\u2013192 (2012).","journal-title":"Nat. Protoc."},{"key":"4584_CR65","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"4584_CR66","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nmeth.2600","volume":"10","author":"P Perez-Pinera","year":"2013","unstructured":"Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR\u2013Cas9-based transcription factors. Nat. Methods 10, 973\u2013976 (2013).","journal-title":"Nat. Methods"},{"key":"4584_CR67","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR\u2013Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"4584_CR68","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"4584_CR69","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"4584_CR70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","volume":"562","author":"GM Findlay","year":"2018","unstructured":"Findlay, G. M. et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562, 217\u2013222 (2018).","journal-title":"Nature"},{"key":"4584_CR71","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1161\/CIRCULATIONAHA.117.032273","volume":"138","author":"N Ma","year":"2018","unstructured":"Ma, N. et al. Determining the pathogenicity of a genomic variant of uncertain significance using CRISPR\/Cas9 and human-induced pluripotent stem cells. Circulation 138, 2666\u20132681 (2018).","journal-title":"Circulation"},{"key":"4584_CR72","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature09915","volume":"473","author":"KJ Brennand","year":"2011","unstructured":"Brennand, K. J. et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221\u2013225 (2011).","journal-title":"Nature"},{"key":"4584_CR73","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2015.06.034","volume":"162","author":"J Mariani","year":"2015","unstructured":"Mariani, J. et al. FOXG1-dependent dysregulation of GABA\/glutamate neuron differentiation in autism spectrum disorders. Cell 162, 375\u2013390 (2015).","journal-title":"Cell"},{"key":"4584_CR74","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41591-020-1023-0","volume":"26","author":"M Koido","year":"2020","unstructured":"Koido, M. et al. Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nat. Med. 26, 1541\u20131548 (2020).","journal-title":"Nat. Med."},{"key":"4584_CR75","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00438-022-01905-2","volume":"297","author":"JRI Coleman","year":"2022","unstructured":"Coleman, J. R. I. Feasibility and application of polygenic score analysis to the morphology of human-induced pluripotent stem cells. Mol. Genet. Genomics 297, 1111\u20131122 (2022).","journal-title":"Mol. Genet. Genomics"},{"key":"4584_CR76","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nature22403","volume":"546","author":"H Kilpinen","year":"2017","unstructured":"Kilpinen, H. et al. Common genetic variation drives molecular heterogeneity in human iPSCs. Nature 546, 370\u2013375 (2017).","journal-title":"Nature"},{"key":"4584_CR77","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nature08494","volume":"461","author":"TA Manolio","year":"2009","unstructured":"Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747\u2013753 (2009).","journal-title":"Nature"},{"key":"4584_CR78","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1161\/CIRCRESAHA.118.312913","volume":"123","author":"DT Paik","year":"2018","unstructured":"Paik, D. T. et al. Large-scale single-cell RNA-seq reveals molecular signatures of heterogeneous populations of human induced pluripotent stem cell-derived endothelial cells. Circ. Res. 123, 443\u2013450 (2018).","journal-title":"Circ. Res."},{"key":"4584_CR79","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41588-021-00801-6","volume":"53","author":"J Jerber","year":"2021","unstructured":"Jerber, J. et al. Population-scale single-cell RNA-seq profiling across dopaminergic neuron differentiation. Nat. Genet. 53, 304\u2013312 (2021).","journal-title":"Nat. Genet."},{"key":"4584_CR80","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1016\/j.cell.2022.09.031","volume":"185","author":"M Kimura","year":"2022","unstructured":"Kimura, M. et al. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH. Cell 185, 4216\u20134232 (2022).","journal-title":"Cell"},{"key":"4584_CR81","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41592-024-02555-5","volume":"22","author":"N Caporale","year":"2025","unstructured":"Caporale, N. et al. Multiplexing cortical brain organoids for the longitudinal dissection of developmental traits at single-cell resolution. Nat. Methods 22, 358\u2013370 (2025).","journal-title":"Nat. Methods"},{"key":"4584_CR82","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-024-07578-8","volume":"631","author":"N Ant\u00f3n-Bola\u00f1os","year":"2024","unstructured":"Ant\u00f3n-Bola\u00f1os, N. et al. Brain Chimeroids reveal individual susceptibility to neurotoxic triggers. Nature 631, 142\u2013149 (2024).","journal-title":"Nature"},{"key":"4584_CR83","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.cell.2016.11.048","volume":"167","author":"B Adamson","year":"2016","unstructured":"Adamson, B. et al. A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867\u20131882 (2016).","journal-title":"Cell"},{"key":"4584_CR84","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1016\/j.cell.2024.07.035","volume":"187","author":"JE Rood","year":"2024","unstructured":"Rood, J. E., Hupalowska, A. & Regev, A. Toward a foundation model of causal cell and tissue biology with a Perturbation Cell and Tissue Atlas. Cell 187, 4520\u20134545 (2024).","journal-title":"Cell"},{"key":"4584_CR85","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.stem.2024.09.017","volume":"31","author":"MM Onesto","year":"2024","unstructured":"Onesto, M. M., Kim, J.-I. & Pasca, S. P. Assembloid models of cell\u2013cell interaction to study tissue and disease biology. Cell Stem Cell 31, 1563\u20131573 (2024).","journal-title":"Cell Stem Cell"},{"key":"4584_CR86","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-025-08808-3","volume":"642","author":"J-I Kim","year":"2025","unstructured":"Kim, J.-I. et al. Human assembloid model of the ascending neural sensory pathway. Nature 642, 143\u2013153 (2025).","journal-title":"Nature"},{"key":"4584_CR87","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.stem.2015.05.004","volume":"16","author":"L Studer","year":"2015","unstructured":"Studer, L., Vera, E. & Cornacchia, D. Programming and reprogramming cellular age in the era of induced pluripotency. Cell Stem Cell 16, 591\u2013600 (2015).","journal-title":"Cell Stem Cell"},{"key":"4584_CR88","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.stem.2015.09.001","volume":"17","author":"J Mertens","year":"2015","unstructured":"Mertens, J. et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell 17, 705\u2013718 (2015).","journal-title":"Cell Stem Cell"},{"key":"4584_CR89","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.stem.2021.04.004","volume":"28","author":"J Mertens","year":"2021","unstructured":"Mertens, J. et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer\u2019s patients. Cell Stem Cell 28, 1533\u20131548 (2021).","journal-title":"Cell Stem Cell"},{"key":"4584_CR90","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.18648","volume":"5","author":"CJ Huh","year":"2016","unstructured":"Huh, C. J. et al. Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. eLife 5, e18648 (2016).","journal-title":"eLife"},{"key":"4584_CR91","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cell.2016.11.052","volume":"167","author":"A Ocampo","year":"2016","unstructured":"Ocampo, A. et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 167, 1719\u20131733 (2016).","journal-title":"Cell"},{"key":"4584_CR92","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.neuron.2017.07.035","volume":"95","author":"SA Sloan","year":"2017","unstructured":"Sloan, S. A. et al. Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells. Neuron 95, 779\u2013790 (2017).","journal-title":"Neuron"},{"key":"4584_CR93","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nature13800","volume":"515","author":"SH Choi","year":"2014","unstructured":"Choi, S. H. et al. A three-dimensional human neural cell culture model of Alzheimer\u2019s disease. Nature 515, 274\u2013278 (2014).","journal-title":"Nature"},{"key":"4584_CR94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCRESAHA.118.313973","volume":"125","author":"A Ebert","year":"2019","unstructured":"Ebert, A. et al. Proteasome-dependent regulation of distinct metabolic states during long-term culture of human iPSC-derived cardiomyocytes. Circ. Res. 125, 90\u2013103 (2019).","journal-title":"Circ. Res."},{"key":"4584_CR95","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13541","volume":"21","author":"A Fathi","year":"2022","unstructured":"Fathi, A. et al. Chemically induced senescence in human stem cell-derived neurons promotes phenotypic presentation of neurodegeneration. Aging Cell 21, e13541 (2022).","journal-title":"Aging Cell"},{"key":"4584_CR96","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.stem.2024.06.001","volume":"31","author":"N Saurat","year":"2024","unstructured":"Saurat, N. et al. Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration. Cell Stem Cell 31, 1162\u20131174 (2024).","journal-title":"Cell Stem Cell"},{"key":"4584_CR97","volume":"9","author":"Z Ao","year":"2022","unstructured":"Ao, Z. et al. Understanding immune-driven brain aging by human brain organoid microphysiological analysis platform. Adv. Sci. (Weinh.) 9, e2200475 (2022).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"4584_CR98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.stem.2011.01.013","volume":"8","author":"HN Nguyen","year":"2011","unstructured":"Nguyen, H. N. et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8, 267\u2013280 (2011).","journal-title":"Cell Stem Cell"},{"key":"4584_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026159","volume":"6","author":"B Byers","year":"2011","unstructured":"Byers, B. et al. SNCA triplication Parkinson\u2019s patient\u2019s iPSC-derived DA neurons accumulate \u03b1-synuclein and are susceptible to oxidative stress. PLoS ONE 6, e26159 (2011).","journal-title":"PLoS ONE"},{"key":"4584_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07201-1","volume":"9","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. A hPSC-based platform to discover gene\u2013environment interactions that impact human \u03b2-cell and dopamine neuron survival. Nat. Commun. 9, 4815 (2018).","journal-title":"Nat. Commun."},{"key":"4584_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120554","volume":"268","author":"SG Ozcebe","year":"2021","unstructured":"Ozcebe, S. G., Bahcecioglu, G., Yue, X. S. & Zorlutuna, P. Effect of cellular and ECM aging on human iPSC-derived cardiomyocyte performance, maturity and senescence. Biomaterials 268, 120554 (2021).","journal-title":"Biomaterials"},{"key":"4584_CR102","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.cell.2022.04.005","volume":"185","author":"T-T Wei","year":"2022","unstructured":"Wei, T.-T. et al. Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. Cell 185, 1676\u20131693 (2022).","journal-title":"Cell"},{"key":"4584_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00917","volume":"8","author":"KC Chang","year":"2017","unstructured":"Chang, K. C. et al. Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment. Front. Physiol. 8, 917 (2017).","journal-title":"Front. Physiol."},{"key":"4584_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00616","volume":"8","author":"S Dutta","year":"2017","unstructured":"Dutta, S. et al. Optimization of an in silico cardiac cell model for proarrhythmia risk assessment. Front. Physiol. 8, 616 (2017).","journal-title":"Front. Physiol."},{"key":"4584_CR105","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004628","volume":"10","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-\u00e0-go-go-related gene) channel\u2013drug binding kinetics and multichannel pharmacology. Circ. Arrhythm. Electrophysiol. 10, e004628 (2017).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"4584_CR106","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/cpt.1184","volume":"105","author":"Z Li","year":"2019","unstructured":"Li, Z. et al. Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative. Clin. Pharmacol. Ther. 105, 466\u2013475 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4584_CR107","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1053\/j.gastro.2020.10.002","volume":"160","author":"T Shinozawa","year":"2021","unstructured":"Shinozawa, T. et al. High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids. Gastroenterology 160, 831\u2013846 (2021).","journal-title":"Gastroenterology"},{"key":"4584_CR108","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.stem.2019.08.002","volume":"25","author":"CA Trujillo","year":"2019","unstructured":"Trujillo, C. A. et al. Complex oscillatory waves emerging from cortical organoids model early human brain network development. Cell Stem Cell 25, 558\u2013569 (2019).","journal-title":"Cell Stem Cell"},{"key":"4584_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06684-2","volume":"9","author":"PR Ormel","year":"2018","unstructured":"Ormel, P. R. et al. Microglia innately develop within cerebral organoids. Nat. Commun. 9, 4167 (2018).","journal-title":"Nat. Commun."},{"key":"4584_CR110","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933\u2013945 (2015).","journal-title":"Cell"},{"key":"4584_CR111","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 8, 1112\u20131129 (2018).","journal-title":"Cancer Discov."},{"key":"4584_CR112","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004052","volume":"4","author":"N Egawa","year":"2012","unstructured":"Egawa, N. et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4, 145ra104 (2012).","journal-title":"Sci. Transl. Med."},{"key":"4584_CR113","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd.2016.245","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: a decade of progress. Nat. Rev. Drug Discov. 16, 115\u2013130 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4584_CR114","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/brain\/awac306","volume":"146","author":"D Ito","year":"2023","unstructured":"Ito, D. et al. Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis. Brain 146, 13\u201319 (2023).","journal-title":"Brain"},{"key":"4584_CR115","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf3962","volume":"9","author":"K Imamura","year":"2017","unstructured":"Imamura, K. et al. The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 9, eaaf3962 (2017).","journal-title":"Sci. Transl. Med."},{"key":"4584_CR116","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.cell.2026.02.008","volume":"189","author":"A Zink","year":"2026","unstructured":"Zink, A. et al. Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy. Cell 189, 1656\u20131679 (2026).","journal-title":"Cell"},{"key":"4584_CR117","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-024-07310-6","volume":"628","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Antisense oligonucleotide therapeutic approach for Timothy syndrome. Nature 628, 818\u2013825 (2024).","journal-title":"Nature"},{"key":"4584_CR118","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nature13775","volume":"513","author":"A Yamashita","year":"2014","unstructured":"Yamashita, A. et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 513, 507\u2013511 (2014).","journal-title":"Nature"},{"key":"4584_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2014.03.019","volume":"7","author":"BJ Wainger","year":"2014","unstructured":"Wainger, B. J. et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 7, 1\u201311 (2014).","journal-title":"Cell Rep."},{"key":"4584_CR120","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.stem.2015.06.013","volume":"17","author":"J McNeish","year":"2015","unstructured":"McNeish, J., Gardner, J. P., Wainger, B. J., Woolf, C. J. & Eggan, K. From dish to bedside: lessons learned while translating findings from a stem cell model of disease to a clinical trial. Cell Stem Cell 17, 8\u201310 (2015).","journal-title":"Cell Stem Cell"},{"key":"4584_CR121","unstructured":"US Congress. S.5002\u2014FDA Modernization Act 2.0, 117th Congress https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/5002 (2022)."},{"key":"4584_CR122","unstructured":"US Food and Drug Administration. FDA\u2019s Predictive Toxicology Roadmap https:\/\/www.fda.gov\/media\/109634\/download (2017)."},{"key":"4584_CR123","doi-asserted-by":"publisher","unstructured":"Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). A strategic roadmap for establishing new approaches to evaluate the safety of chemicals and medical products in the United States. National Toxicology Program https:\/\/doi.org\/10.22427\/NTP-ICCVAM-ROADMAP2018 (2018).","DOI":"10.22427\/NTP-ICCVAM-ROADMAP2018"},{"key":"4584_CR124","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41573-025-01182-9","volume":"24","author":"M Beilmann","year":"2025","unstructured":"Beilmann, M. et al. Application of new approach methodologies for nonclinical safety assessment of drug candidates. Nat. Rev. Drug Discov. 24, 705\u2013725 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4584_CR125","unstructured":"US Congress. S.355\u2014FDA Modernization Act 3.0, 119th Congress https:\/\/www.congress.gov\/bill\/119th-congress\/senate-bill\/355 (2025)."},{"key":"4584_CR126","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/d41586-025-03344-6","volume":"646","author":"TJ Herron","year":"2025","unstructured":"Herron, T. J. et al. Alternatives to animal testing are the future\u2014it\u2019s time that journals, funders and scientists embrace them. Nature 646, 799\u2013801 (2025).","journal-title":"Nature"},{"key":"4584_CR127","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/toxsci\/kfaa058","volume":"176","author":"U Saleem","year":"2020","unstructured":"Saleem, U. et al. Blinded, multicenter evaluation of drug-induced changes in contractility using human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 176, 103\u2013123 (2020).","journal-title":"Toxicol. Sci."},{"key":"4584_CR128","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.tibtech.2025.11.016","volume":"44","author":"T de Korte","year":"2026","unstructured":"de Korte, T. et al. Industrialization of 3D hiPSC-cardiac microtissues for high-throughput cardiac safety and drug discovery screening. Trends Biotechnol. 44, 1100\u20131127 (2026).","journal-title":"Trends Biotechnol."},{"key":"4584_CR129","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). E14\/S7B Questions & Answers (Step 4) https:\/\/database.ich.org\/sites\/default\/files\/E14-S7B_QAs_Step4_2022_0221.pdf (2022)."},{"key":"4584_CR130","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/toxsci\/kfac095","volume":"190","author":"X Yang","year":"2022","unstructured":"Yang, X., Ribeiro, A. J. S., Pang, L. & Strauss, D. G. Use of human iPSC-CMs in nonclinical regulatory studies for cardiac safety assessment. Toxicol. Sci. 190, 117\u2013126 (2022).","journal-title":"Toxicol. Sci."},{"key":"4584_CR131","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/toxsci\/kfaf064","volume":"206","author":"NE Simpson","year":"2025","unstructured":"Simpson, N. E., Bourcier, T. & Sadrieh, N. A Food and Drug Administration\/Center for Drug Evaluation and Research nonclinical perspective on the use of human-induced pluripotent stem cell-derived cardiomyocyte data for cardiovascular safety assessment and regulatory decisions. Toxicol. Sci. 206, 219\u2013227 (2025).","journal-title":"Toxicol. Sci."},{"key":"4584_CR132","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000099259","volume":"92","author":"P Zamiri","year":"2007","unstructured":"Zamiri, P., Sugita, S. & Streilein, J. W. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem. Immunol. Allergy 92, 86\u201393 (2007).","journal-title":"Chem. Immunol. Allergy"},{"key":"4584_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072217","volume":"9","author":"S Sugita","year":"2020","unstructured":"Sugita, S. et al. HLA-matched allogeneic iPS cells-derived RPE transplantation for macular degeneration. J. Clin. Med. 9, 2217 (2020).","journal-title":"J. Clin. Med."},{"key":"4584_CR134","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.stem.2023.11.004","volume":"30","author":"Y Hirami","year":"2023","unstructured":"Hirami, Y. et al. Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa. Cell Stem Cell 30, 1585\u20131596 (2023).","journal-title":"Cell Stem Cell"},{"key":"4584_CR135","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N. Engl. J. Med. 382, 1926\u20131932 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4584_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1182209","volume":"10","author":"T Kawamura","year":"2023","unstructured":"Kawamura, T. et al. Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: first three case reports. Front. Cardiovasc. Med. 10, 1182209 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"4584_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.950829","volume":"9","author":"S Miyagawa","year":"2022","unstructured":"Miyagawa, S. et al. Case report: transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy. Front. Cardiovasc. Med. 9, 950829 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"4584_CR138","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-024-08463-0","volume":"639","author":"A-F Jebran","year":"2025","unstructured":"Jebran, A.-F. et al. Engineered heart muscle allografts for heart repair in primates and humans. Nature 639, 503\u2013511 (2025).","journal-title":"Nature"},{"key":"4584_CR139","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056264","volume":"12","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I\/IIa dose-escalation clinical trial. BMJ Open 12, e056264 (2022).","journal-title":"BMJ Open"},{"key":"4584_CR140","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa2513525","volume":"394","author":"W-H Zimmermann","year":"2026","unstructured":"Zimmermann, W.-H. et al. Stem-cell-derived biologic ventricular assist tissue in heart failure. N. Engl. J. Med. 394, 1991\u20132001 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4584_CR141","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1172\/JCI80575","volume":"125","author":"E Neofytou","year":"2015","unstructured":"Neofytou, E., O\u2019Brien, C. G., Couture, L. A. & Wu, J. C. Hurdles to clinical translation of human induced pluripotent stem cells. J. Clin. Invest. 125, 2551\u20132557 (2015).","journal-title":"J. Clin. Invest."},{"key":"4584_CR142","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41587-024-02360-7","volume":"43","author":"ES Ng","year":"2025","unstructured":"Ng, E. S. et al. Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells. Nat. Biotechnol. 43, 1274\u20131287 (2025).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR143","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1182\/blood-2024-198684","volume":"144","author":"V Bachanova","year":"2024","unstructured":"Bachanova, V. et al. Safety and efficacy of FT522, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy with alloimmune defense receptor (ADR) in relapsed\/refractory B-cell lymphoma. Blood 144, 6543\u20136544 (2024).","journal-title":"Blood"},{"key":"4584_CR144","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405, 127\u2013136 (2025).","journal-title":"Lancet"},{"key":"4584_CR145","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1182\/blood-2023-189132","volume":"142","author":"JE Maakaron","year":"2023","unstructured":"Maakaron, J. E. et al. Phase I study of FT538\u2009+\u2009daratumumab for treatment of r\/r AML. Blood 142, 4842\u20134843 (2023).","journal-title":"Blood"},{"key":"4584_CR146","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-5185","volume":"82","author":"K Harano","year":"2022","unstructured":"Harano, K. et al. Abstract 5185: first in human trial of off-the shelf iPS derived anti-GPC3 NK cells for recurrent ovarian clear cell carcinoma with peritoneal dissemination. Cancer Res. 82, 5185 (2022).","journal-title":"Cancer Res."},{"key":"4584_CR147","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood-2023-182313","volume":"142","author":"I Ramachandran","year":"2023","unstructured":"Ramachandran, I. et al. Multiple doses of CNTY-101, an iPSC-derived allogeneic CD19 targeting CAR-NK product, are safe and result in tumor microenvironment changes associated with response: a case study. Blood 142, 1654\u20131655 (2023).","journal-title":"Blood"},{"key":"4584_CR148","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1016\/S2352-3026(25)00142-5","volume":"12","author":"P Strati","year":"2025","unstructured":"Strati, P. et al. Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. Lancet Haematol. 12, e505\u2013e515 (2025).","journal-title":"Lancet Haematol."},{"key":"4584_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102784","volume":"21","author":"J Barry","year":"2026","unstructured":"Barry, J. et al. Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies. Stem Cell Reports 21, 102784 (2026).","journal-title":"Stem Cell Reports"},{"key":"4584_CR150","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05493-9","volume":"82","author":"J Yun","year":"2024","unstructured":"Yun, J. et al. Transcriptome and epigenome dynamics of the clonal heterogeneity of human induced pluripotent stem cells for cardiac differentiation. Cell. Mol. Life Sci. 82, 2 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"4584_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102741","volume":"21","author":"MK Carpenter","year":"2026","unstructured":"Carpenter, M. K. & Ludwig, T. E. Pluripotent stem cell lines available for use in clinical applications: a comprehensive overview. Stem Cell Reports 21, 102741 (2026).","journal-title":"Stem Cell Reports"},{"key":"4584_CR152","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature09342","volume":"467","author":"K Kim","year":"2010","unstructured":"Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285\u2013290 (2010).","journal-title":"Nature"},{"key":"4584_CR153","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nbt.1667","volume":"28","author":"JM Polo","year":"2010","unstructured":"Polo, J. M. et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28, 848\u2013855 (2010).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR154","doi-asserted-by":"publisher","first-page":"E11111","DOI":"10.1073\/pnas.1708991114","volume":"114","author":"M-T Zhao","year":"2017","unstructured":"Zhao, M.-T. et al. Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs. Proc. Natl Acad. Sci. USA 114, E11111\u2013E11120 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4584_CR155","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nature09871","volume":"471","author":"SM Hussein","year":"2011","unstructured":"Hussein, S. M. et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58\u201362 (2011).","journal-title":"Nature"},{"key":"4584_CR156","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature09805","volume":"471","author":"A Gore","year":"2011","unstructured":"Gore, A. et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 471, 63\u201367 (2011).","journal-title":"Nature"},{"key":"4584_CR157","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.stem.2010.12.003","volume":"8","author":"LC Laurent","year":"2011","unstructured":"Laurent, L. C. et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8, 106\u2013118 (2011).","journal-title":"Cell Stem Cell"},{"key":"4584_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering9030092","volume":"9","author":"B Lee","year":"2022","unstructured":"Lee, B. et al. Cell culture process scale-up challenges for commercial-scale manufacturing of allogeneic pluripotent stem cell products. Bioengineering (Basel) 9, 92 (2022).","journal-title":"Bioengineering (Basel)"},{"key":"4584_CR159","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Comparability of Biotechnological\/Biological Products Subject to Changes in their Manufacturing Process: Q5E https:\/\/database.ich.org\/sites\/default\/files\/Q5E%20Guideline.pdf (2004)."},{"key":"4584_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115744","volume":"229","author":"A Haase","year":"2026","unstructured":"Haase, A., Ruhparwar, A. & Martin, U. GMP-compliant manufacturing of iPSC-derived therapeutic cell products: technologies, applications, risks and limitations. Adv. Drug Deliv. Rev. 229, 115744 (2026).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"4584_CR161","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Pharmaceutical Development: Q8(R2) https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf (2009)."},{"key":"4584_CR162","unstructured":"US Food and Drug Administration. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products https:\/\/www.fda.gov\/media\/79856\/download (2011)."},{"key":"4584_CR163","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nbt.3525","volume":"34","author":"YY Lipsitz","year":"2016","unstructured":"Lipsitz, Y. Y., Timmins, N. E. & Zandstra, P. W. Quality cell therapy manufacturing by design. Nat. Biotechnol. 34, 393\u2013400 (2016).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR164","unstructured":"US Food and Drug Administration. Long Term Follow-Up after Administration of Human gGene Therapy Products: Guidance for Industry https:\/\/www.fda.gov\/media\/113768\/download (2020)."},{"key":"4584_CR165","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","volume":"16","author":"R Lovell-Badge","year":"2021","unstructured":"Lovell-Badge, R. et al. ISSCR Guidelines for Stem Cell Research and Clinical Translation: the 2021 update. Stem Cell Reports 16, 1398\u20131408 (2021).","journal-title":"Stem Cell Reports"},{"key":"4584_CR166","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm.3267","volume":"19","author":"AS Lee","year":"2013","unstructured":"Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L. & Wu, J. C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998\u20131004 (2013).","journal-title":"Nat. Med."},{"key":"4584_CR167","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature10135","volume":"474","author":"T Zhao","year":"2011","unstructured":"Zhao, T., Zhang, Z.-N., Rong, Z. & Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature 474, 212\u2013215 (2011).","journal-title":"Nature"},{"key":"4584_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02237-4","volume":"4","author":"S Petrus-Reurer","year":"2021","unstructured":"Petrus-Reurer, S. et al. Immunological considerations and challenges for regenerative cellular therapies. Commun. Biol. 4, 798 (2021).","journal-title":"Commun. Biol."},{"key":"4584_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-020-00125-8","volume":"40","author":"R Otsuka","year":"2020","unstructured":"Otsuka, R., Wada, H., Murata, T. & Seino, K.-I. Immune reaction and regulation in transplantation based on pluripotent stem cell technology. Inflamm. Regen. 40, 12 (2020).","journal-title":"Inflamm. Regen."},{"key":"4584_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03308-5","volume":"14","author":"ME Bogomiakova","year":"2023","unstructured":"Bogomiakova, M. E. et al. iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors. Stem Cell Res. Ther. 14, 77 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"4584_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/rme.14.93","volume":"10","author":"PW Andrews","year":"2015","unstructured":"Andrews, P. W. et al. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen. Med. 10, 1\u201344 (2015).","journal-title":"Regen. Med."},{"key":"4584_CR172","unstructured":"European Parliament and the Council of the European Union. Regulation (EC) no. 1394\/2007 on Advanced Therapy Medicinal Products https:\/\/eur-lex.europa.eu\/eli\/reg\/2007\/1394\/oj\/eng (2007)."},{"key":"4584_CR173","unstructured":"US Food and Drug Administration Center for Biologics Evaluation and Research (CBER). Cellular & Gene Therapy Products https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products (2026)."},{"key":"4584_CR174","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41587-024-02196-1","volume":"42","author":"L Lyu","year":"2024","unstructured":"Lyu, L., Feng, Y., Huang, B., Xu, R.-H. & Hu, Y. Mapping the global landscape for induced pluripotent stem cells from patents and clinical trials. Nat. Biotechnol. 42, 563\u2013569 (2024).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR175","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1126\/science.1229566","volume":"339","author":"M Gymrek","year":"2013","unstructured":"Gymrek, M., McGuire, A. L., Golan, D., Halperin, E. & Erlich, Y. Identifying personal genomes by surname inference. Science 339, 321\u2013324 (2013).","journal-title":"Science"},{"key":"4584_CR176","doi-asserted-by":"publisher","first-page":"10441","DOI":"10.1073\/pnas.1902566116","volume":"116","author":"X Han","year":"2019","unstructured":"Han, X. et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc. Natl Acad. Sci. USA 116, 10441\u201310446 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4584_CR177","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-019-1168-5","volume":"569","author":"A Veres","year":"2019","unstructured":"Veres, A. et al. Charting cellular identity during human in vitro \u03b2-cell differentiation. Nature 569, 368\u2013373 (2019).","journal-title":"Nature"},{"key":"4584_CR178","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cell.2014.09.040","volume":"159","author":"FW Pagliuca","year":"2014","unstructured":"Pagliuca, F. W. et al. Generation of functional human pancreatic \u03b2 cells in vitro. Cell 159, 428\u2013439 (2014).","journal-title":"Cell"},{"key":"4584_CR179","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.4114","volume":"36","author":"L da Cruz","year":"2018","unstructured":"da Cruz, L. et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat. Biotechnol. 36, 328\u2013337 (2018).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR180","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature12271","volume":"499","author":"T Takebe","year":"2013","unstructured":"Takebe, T. et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499, 481\u2013484 (2013).","journal-title":"Nature"},{"key":"4584_CR181","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.bbrc.2013.12.142","volume":"443","author":"A Odawara","year":"2014","unstructured":"Odawara, A., Saitoh, Y., Alhebshi, A. H., Gotoh, M. & Suzuki, I. Long-term electrophysiological activity and pharmacological response of a human induced pluripotent stem cell-derived neuron and astrocyte co-culture. Biochem. Biophys. Res. Commun. 443, 1176\u20131181 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"4584_CR182","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.cell.2016.11.038","volume":"167","author":"A Dixit","year":"2016","unstructured":"Dixit, A. et al. Perturb-seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell 167, 1853\u20131866 (2016).","journal-title":"Cell"},{"key":"4584_CR183","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.celrep.2018.03.091","volume":"23","author":"SM Maffioletti","year":"2018","unstructured":"Maffioletti, S. M. et al. Three-dimensional human iPSC-derived artificial skeletal muscles model muscular dystrophies and enable multilineage tissue engineering. Cell Rep. 23, 899\u2013908 (2018).","journal-title":"Cell Rep."},{"key":"4584_CR184","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nbt.3392","volume":"33","author":"R Morizane","year":"2015","unstructured":"Morizane, R. et al. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat. Biotechnol. 33, 1193\u20131200 (2015).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR185","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.stemcr.2020.10.005","volume":"15","author":"KO Brand\u00e3o","year":"2020","unstructured":"Brand\u00e3o, K. O. et al. Isogenic sets of hiPSC-CMs harboring distinct KCNH2 mutations differ functionally and in susceptibility to drug-induced arrhythmias. Stem Cell Reports 15, 1127\u20131139 (2020).","journal-title":"Stem Cell Reports"},{"key":"4584_CR186","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.stem.2016.07.006","volume":"19","author":"E Matsa","year":"2016","unstructured":"Matsa, E. et al. Transcriptome profiling of patient-specific human iPSC-cardiomyocytes predicts individual drug safety and efficacy responses in vitro. Cell Stem Cell 19, 311\u2013325 (2016).","journal-title":"Cell Stem Cell"},{"key":"4584_CR187","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neuron.2019.07.014","volume":"104","author":"R Tian","year":"2019","unstructured":"Tian, R. et al. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron 104, 239\u2013255 (2019).","journal-title":"Neuron"},{"key":"4584_CR188","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.stem.2016.11.005","volume":"20","author":"I Carcamo-Orive","year":"2017","unstructured":"Carcamo-Orive, I. et al. Analysis of transcriptional variability in a large human iPSC library reveals genetic and non-genetic determinants of heterogeneity. Cell Stem Cell 20, 518\u2013532 (2017).","journal-title":"Cell Stem Cell"},{"key":"4584_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104662","volume":"114","author":"AM Avila","year":"2020","unstructured":"Avila, A. M. et al. An FDA\/CDER perspective on nonclinical testing strategies: classical toxicology approaches and new approach methodologies (NAMs). Regul. Toxicol. Pharmacol. 114, 104662 (2020).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"4584_CR190","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.4155\/bio-2019-0271","volume":"11","author":"S Piccoli","year":"2019","unstructured":"Piccoli, S. et al. 2019 White paper on recent issues in bioanalysis: FDA immunogenicity guidance, gene therapy, critical reagents, biomarkers and flow cytometry validation (part 3\u2014recommendations on 2019 FDA immunogenicity guidance, gene therapy bioanalytical challenges, strategies for critical reagent management, biomarker assay validation, flow cytometry validation & CLSI H62). Bioanalysis 11, 2207\u20132244 (2019).","journal-title":"Bioanalysis"},{"key":"4584_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.105026","volume":"125","author":"MP Dent","year":"2021","unstructured":"Dent, M. P. et al. Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients. Regul. Toxicol. Pharmacol. 125, 105026 (2021).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"4584_CR192","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nmeth.3507","volume":"12","author":"D Paull","year":"2015","unstructured":"Paull, D. et al. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat. Methods 12, 885\u2013892 (2015).","journal-title":"Nat. Methods"},{"key":"4584_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28423-4","volume":"13","author":"L Schiff","year":"2022","unstructured":"Schiff, L. et al. Integrating deep learning and unbiased automated high-content screening to identify complex disease signatures in human fibroblasts. Nat. Commun. 13, 1590 (2022).","journal-title":"Nat. Commun."},{"key":"4584_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.580352","volume":"8","author":"A Elanzew","year":"2020","unstructured":"Elanzew, A. et al. The StemCellFactory: a modular system integration for automated generation and expansion of human induced pluripotent stem cells. Front. Bioeng. Biotechnol. 8, 580352 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"4584_CR195","first-page":"30","volume":"39","author":"D Pamies","year":"2022","unstructured":"Pamies, D. et al. Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0). ALTEX 39, 30\u201370 (2022).","journal-title":"ALTEX"},{"key":"4584_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81129-3","volume":"11","author":"I Boussaad","year":"2021","unstructured":"Boussaad, I. et al. Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening. Sci. Rep. 11, 1439 (2021).","journal-title":"Sci. Rep."},{"key":"4584_CR197","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.stem.2018.04.022","volume":"22","author":"SM Czerniecki","year":"2018","unstructured":"Czerniecki, S. M. et al. High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping. Cell Stem Cell 22, 929\u2013940 (2018).","journal-title":"Cell Stem Cell"},{"key":"4584_CR198","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/2472630320972110","volume":"26","author":"V Truong","year":"2021","unstructured":"Truong, V. et al. Automating human induced pluripotent stem cell culture and differentiation of iPSC-derived retinal pigment epithelium for personalized drug testing. SLAS Technol. 26, 287\u2013299 (2021).","journal-title":"SLAS Technol."},{"key":"4584_CR199","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/nprot.2016.105","volume":"11","author":"M-A Bray","year":"2016","unstructured":"Bray, M.-A. et al. Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat. Protoc. 11, 1757\u20131774 (2016).","journal-title":"Nat. Protoc."},{"key":"4584_CR200","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nbt.4091","volume":"36","author":"L Haghverdi","year":"2018","unstructured":"Haghverdi, L., Lun, A. T. L., Morgan, M. D. & Marioni, J. C. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol. 36, 421\u2013427 (2018).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR201","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jare.2025.07.030","volume":"82","author":"Y-G Park","year":"2026","unstructured":"Park, Y.-G. et al. A machine learning platform for genotype-specific cardiotoxicity risk prediction using patient-derived iPSC-CMs. J. Adv. Res. 82, 381\u2013396 (2026).","journal-title":"J. Adv. Res."},{"key":"4584_CR202","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.68714","volume":"10","author":"F Grafton","year":"2021","unstructured":"Grafton, F. et al. Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes. eLife 10, e68714 (2021).","journal-title":"eLife"},{"key":"4584_CR203","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41592-025-02772-6","volume":"22","author":"C Ahlmann-Eltze","year":"2025","unstructured":"Ahlmann-Eltze, C., Huber, W. & Anders, S. Deep-learning-based gene perturbation effect prediction does not yet outperform simple linear baselines. Nat. Methods 22, 1657\u20131661 (2025).","journal-title":"Nat. Methods"},{"key":"4584_CR204","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.stem.2024.10.007","volume":"31","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. CRISPRi\/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity. Cell Stem Cell 31, 1760\u20131776 (2024).","journal-title":"Cell Stem Cell"},{"key":"4584_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19597-w","volume":"11","author":"AG Kusne","year":"2020","unstructured":"Kusne, A. G. et al. On-the-fly closed-loop materials discovery via Bayesian active learning. Nat. Commun. 11, 5966 (2020).","journal-title":"Nat. Commun."},{"key":"4584_CR206","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-pharmtox-022724-095035","volume":"65","author":"Z Yildirim","year":"2025","unstructured":"Yildirim, Z., Swanson, K., Wu, X., Zou, J. & Wu, J. Next-gen therapeutics: pioneering drug discovery with iPSCs, genomics, AI, and clinical trials in a dish. Annu. Rev. Pharmacol. Toxicol. 65, 71\u201390 (2025).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"4584_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100770","volume":"5","author":"D Sakai","year":"2025","unstructured":"Sakai, D. et al. Transplant of induced pluripotent stem cell-derived retinal pigment epithelium strips for macular degeneration and retinitis pigmentosa. Ophthalmol. Sci. 5, 100770 (2025).","journal-title":"Ophthalmol. Sci."},{"key":"4584_CR208","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(24)01764-1","volume":"404","author":"T Soma","year":"2024","unstructured":"Soma, T. et al. Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan. Lancet 404, 1929\u20131939 (2024).","journal-title":"Lancet"},{"key":"4584_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101847","volume":"6","author":"M Hirayama","year":"2025","unstructured":"Hirayama, M. et al. A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous keratopathy. Cell Rep. Med. 6, 101847 (2025).","journal-title":"Cell Rep. Med."},{"key":"4584_CR210","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.reth.2021.08.005","volume":"18","author":"K Sugai","year":"2021","unstructured":"Sugai, K. et al. First-in-human clinical trial of transplantation of iPSC-derived NS\/PCs in subacute complete spinal cord injury: study protocol. Regen. Ther. 18, 321\u2013333 (2021).","journal-title":"Regen. Ther."},{"key":"4584_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2026.06.051","author":"A Zhang","year":"2026","unstructured":"Zhang, A. et al. Management of engraftment arrhythmias associated with human-induced pluripotent stem cell-derived cardiomyocytes transplantation. Heart Rhythm https:\/\/doi.org\/10.1016\/j.hrthm.2026.06.051 (2026).","journal-title":"Heart Rhythm"},{"key":"4584_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66801-w","volume":"16","author":"T Iinuma","year":"2025","unstructured":"Iinuma, T. et al. Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial. Nat. Commun. 16, 11666 (2025).","journal-title":"Nat. Commun."},{"key":"4584_CR213","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7580","volume":"41","author":"K Patel","year":"2023","unstructured":"Patel, K. et al. The ELiPSE-1 study: a phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies. J. Clin. Oncol. 41, TPS7580 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4584_CR214","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1182\/blood.2022017296","volume":"140","author":"N Sugimoto","year":"2022","unstructured":"Sugimoto, N. et al. iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study. Blood 140, 2398\u20132402 (2022).","journal-title":"Blood"},{"key":"4584_CR215","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1182\/bloodadvances.2022008512","volume":"6","author":"N Sugimoto","year":"2022","unstructured":"Sugimoto, N. et al. Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial. Blood Adv. 6, 6056\u20136069 (2022).","journal-title":"Blood Adv."},{"key":"4584_CR216","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1016\/j.cell.2024.09.004","volume":"187","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell 187, 6152\u20136164 (2024).","journal-title":"Cell"},{"key":"4584_CR217","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41591-020-1050-x","volume":"26","author":"AJC Bloor","year":"2020","unstructured":"Bloor, A. J. C. et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat. Med. 26, 1720\u20131725 (2020).","journal-title":"Nat. Med."},{"key":"4584_CR218","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/s41591-024-02990-z","volume":"30","author":"K Kelly","year":"2024","unstructured":"Kelly, K. et al. Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease. Nat. Med. 30, 1556\u20131558 (2024).","journal-title":"Nat. Med."},{"key":"4584_CR219","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.stem.2024.12.005","volume":"32","author":"A Kirkeby","year":"2025","unstructured":"Kirkeby, A., Main, H. & Carpenter, M. Pluripotent stem-cell-derived therapies in clinical trial: a 2025 update. Cell Stem Cell 32, 10\u201337 (2025).","journal-title":"Cell Stem Cell"},{"key":"4584_CR220","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.1172482","volume":"324","author":"J Yu","year":"2009","unstructured":"Yu, J. et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797\u2013801 (2009).","journal-title":"Science"},{"key":"4584_CR221","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1126\/science.1151526","volume":"318","author":"J Yu","year":"2007","unstructured":"Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917\u20131920 (2007).","journal-title":"Science"},{"key":"4584_CR222","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.590581","volume":"8","author":"T Qi","year":"2020","unstructured":"Qi, T. et al. Base editing mediated generation of point mutations into human pluripotent stem cells for modeling disease. Front. Cell Dev. Biol. 8, 590581 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"4584_CR223","doi-asserted-by":"publisher","DOI":"10.3390\/genes11050511","volume":"11","author":"D S\u00fcr\u00fcn","year":"2020","unstructured":"S\u00fcr\u00fcn, D. et al. Efficient generation and correction of mutations in human iPS cells utilizing mRNAs of CRISPR base editors and prime editors. Genes (Basel) 11, 511 (2020).","journal-title":"Genes (Basel)"},{"key":"4584_CR224","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41587-023-01784-x","volume":"42","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat. Biotechnol. 42, 413\u2013423 (2024).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR225","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2019-0065","volume":"5","author":"AP Ramme","year":"2019","unstructured":"Ramme, A. P. et al. Autologous induced pluripotent stem cell-derived four-organ-chip. Future Sci. OA 5, FSO413 (2019).","journal-title":"Future Sci. OA"},{"key":"4584_CR226","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature09941","volume":"472","author":"M Eiraku","year":"2011","unstructured":"Eiraku, M. et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 472, 51\u201356 (2011).","journal-title":"Nature"},{"key":"4584_CR227","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","volume":"134","author":"I-H Park","year":"2008","unstructured":"Park, I.-H. et al. Disease-specific induced pluripotent stem cells. Cell 134, 877\u2013886 (2008).","journal-title":"Cell"},{"key":"4584_CR228","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.aaf6116","volume":"352","author":"PP Garcez","year":"2016","unstructured":"Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816\u2013818 (2016).","journal-title":"Science"},{"key":"4584_CR229","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/toxsci\/kfr158","volume":"123","author":"L Guo","year":"2011","unstructured":"Guo, L. et al. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 123, 281\u2013289 (2011).","journal-title":"Toxicol. Sci."},{"key":"4584_CR230","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033131","volume":"9","author":"K Imamura","year":"2019","unstructured":"Imamura, K. et al. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. BMJ Open 9, e033131 (2019).","journal-title":"BMJ Open"},{"key":"4584_CR231","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","volume":"81","author":"T Colatsky","year":"2016","unstructured":"Colatsky, T. et al. The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative\u2014update on progress. J. Pharmacol. Toxicol. Methods 81, 15\u201320 (2016).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"4584_CR232","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/d41586-026-00585-x","volume":"651","author":"A Mullard","year":"2026","unstructured":"Mullard, A. First-of-a-kind stem-cell therapies set for approval in Japan. Nature 651, 13\u201314 (2026).","journal-title":"Nature"},{"key":"4584_CR233","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/nbt.1503","volume":"26","author":"T Aasen","year":"2008","unstructured":"Aasen, T. et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26, 1276\u20131284 (2008).","journal-title":"Nat. Biotechnol."},{"key":"4584_CR234","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.stem.2021.08.015","volume":"28","author":"G Popova","year":"2021","unstructured":"Popova, G. et al. Human microglia states are conserved across experimental models and regulate neural stem cell responses in chimeric organoids. Cell Stem Cell 28, 2153\u20132166 (2021).","journal-title":"Cell Stem Cell"},{"key":"4584_CR235","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.stem.2019.12.007","volume":"26","author":"J-M Faustino Martins","year":"2020","unstructured":"Faustino Martins, J.-M. et al. Self-organizing 3D human trunk neuromuscular organoids. Cell Stem Cell 26, 172\u2013186 (2020).","journal-title":"Cell Stem Cell"},{"key":"4584_CR236","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.stem.2019.05.011","volume":"24","author":"GD Vatine","year":"2019","unstructured":"Vatine, G. D. et al. Human iPSC-derived blood\u2013brain barrier chips enable disease modeling and personalized medicine applications. Cell Stem Cell 24, 995\u20131005 (2019).","journal-title":"Cell Stem Cell"},{"key":"4584_CR237","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10588-0","volume":"10","author":"T-E Park","year":"2019","unstructured":"Park, T.-E. et al. Hypoxia-enhanced blood\u2013brain barrier chip recapitulates human barrier function and shuttling of drugs and antibodies. Nat. Commun. 10, 2621 (2019).","journal-title":"Nat. Commun."},{"key":"4584_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114247","volume":"43","author":"R Moerkens","year":"2024","unstructured":"Moerkens, R. et al. An iPSC-derived small intestine-on-chip with self-organizing epithelial, mesenchymal, and neural cells. Cell Rep. 43, 114247 (2024).","journal-title":"Cell Rep."},{"key":"4584_CR239","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"4584_CR240","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.celrep.2015.04.007","volume":"11","author":"FT Merkle","year":"2015","unstructured":"Merkle, F. T. et al. Efficient CRISPR\u2013Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus. Cell Rep. 11, 875\u2013883 (2015).","journal-title":"Cell Rep."},{"key":"4584_CR241","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u00b7T to G\u00b7C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"4584_CR242","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"PJ Chen","year":"2021","unstructured":"Chen, P. J. et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 184, 5635\u20135652 (2021).","journal-title":"Cell"},{"key":"4584_CR243","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymeth.2015.12.012","volume":"101","author":"F Oceguera-Yanez","year":"2016","unstructured":"Oceguera-Yanez, F. et al. Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives. Methods 101, 43\u201355 (2016).","journal-title":"Methods"},{"key":"4584_CR244","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/mt.2015.100","volume":"23","author":"S Yagyu","year":"2015","unstructured":"Yagyu, S., Hoyos, V., Del Bufalo, F. & Brenner, M. K. An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells. Mol. Ther. 23, 1475\u20131485 (2015).","journal-title":"Mol. Ther."},{"key":"4584_CR245","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1161\/CIRCULATIONAHA.113.001883","volume":"127","author":"P Liang","year":"2013","unstructured":"Liang, P. et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127, 1677\u20131691 (2013).","journal-title":"Circulation"},{"key":"4584_CR246","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.stem.2019.02.015","volume":"24","author":"JZ Zhang","year":"2019","unstructured":"Zhang, J. Z. et al. A human iPSC double-reporter system enables purification of cardiac lineage subpopulations with distinct function and drug response profiles. Cell Stem Cell 24, 802\u2013811 (2019).","journal-title":"Cell Stem Cell"},{"key":"4584_CR247","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41586-024-08172-8","volume":"635","author":"Z He","year":"2024","unstructured":"He, Z. et al. An integrated transcriptomic cell atlas of human neural organoids. Nature 635, 690\u2013698 (2024).","journal-title":"Nature"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04584-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:02:45Z","timestamp":1789480965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04584-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":247,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4584"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04584-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L. serves on the scientific advisory board of Imnewrun. T.H. is an employee of Greenstone Biosciences. L.S. is a cofounder and advisor of BlueRock Therapeutics and DaCapo Brainscience. C.L.M. is a cofounder of Pluriomics B.V. (now Ncardia B.V.) and serves on the scientific advisory board of HeartBeat.bio AG. J.C.W. is a cofounder and serves on the scientific advisory board of Greenstone Biosciences.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}